This search looks for keywords in all of the website’s content. Search tips
Filter by
VeterinaryRegulatory and procedural guidanceMaximum residue limitResearch and development
During the 2020-23 COVID-19 public health emergency, the European Medicines Agency (EMA) provided guidance for medicine developers and pharmaceutical companies to help speed up development and approval for COVID-19 medicines and address regulatory challenges arising from the pandemic.
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific advice
HumanCOVID-19Clinical trialsCompassionate useRegulatory and procedural guidanceMedicine shortagesResearch and developmentScientific adviceVaccines
EventHumanMedicine shortagesResearch and development
The European Medicines Agency (EMA) publishes assessment reports on maximum residue limits for active substances contained in veterinary medicines, which have been assessed by the EMA's Committee for Medicinal Products for Veterinary Use (CVMP) and are currently pending the adoption of a legally binding Regulation by the European Commission.
VeterinaryRegulatory and procedural guidanceMaximum residue limitMedicinesResearch and development